Royalty Pharma Statistics
Royalty Pharma (RPD) Stock Statistics & Valuation Metrics
Total Valuation
Royalty Pharma has a market cap or net worth of EUR 35.76B. The enterprise value is EUR 43.51B.
- Market Cap
- EUR 35.76B
- Enterprise Value
- EUR 43.51B
Share Statistics
Royalty Pharma has 445,265,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 445,265,800
- Owned by Insiders
- 1.57%
- Owned by Institutions
- 66.43%
Financial Efficiency
Royalty Pharma’s return on equity (ROE) is 0.12 and return on invested capital (ROIC) is 8.95%.
- Return on Equity (ROE)
- 0.12
- Return on Assets (ROA)
- 0.04
- Return on Invested Capital (ROIC)
- 8.95%
- Return on Capital Employed (ROCE)
- 0.08
- Revenue Per Employee
- 23.78M
- Profits Per Employee
- 7.71M
- Employee Count
- 100
- Asset Turnover
- 0.12
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Royalty Pharma is 41.04. Royalty Pharma’s PEG ratio is -1.81.
- PE Ratio
- 41.04
- PS Ratio
- 11.66
- PB Ratio
- 4.47
- Price to FCF
- 10.31
- Price to Operating Cash Flow
- 10.33
- PEG Ratio
- -1.81
Income Statement
In the last 12 months, Royalty Pharma had revenue of 2.38B and earned 770.95M in profits. Earnings per share was 2.33.
- Revenue
- 2.38B
- Gross Profit
- 2.38B
- Operating Income
- 1.56B
- Pretax Income
- 1.32B
- Net Income
- 770.95M
- EBITDA
- 1.64B
- Earnings Per Share (EPS)
- 2.33
Cash Flow
In the last 12 months, operating cash flow was 2.96B and capital expenditures 0, giving a free cash flow of 2.96B billion.
- Operating Cash Flow
- 2.96B
- Free Cash Flow
- 2.96B
- Free Cash Flow per Share
- 6.64
Dividends & Yields
Royalty Pharma pays an annual dividend of ―, resulting in a dividend yield of 1.35%
- Dividend Per Share
- ―
- Dividend Yield
- 1.35%
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 9.70%
- Earnings Yield
- 2.20%
Stock Price Statistics
- Beta
- 0.32
- 52-Week Price Change
- 90.51%
- 50-Day Moving Average
- 54.19
- 200-Day Moving Average
- 46.95
- Relative Strength Index (RSI)
- 76.44
- Average Volume (3m)
- 68
Important Dates
Royalty Pharma upcoming earnings date is Feb 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Feb 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Royalty Pharma as a current ratio of 0.97, with Debt / Equity ratio of 138.20%
- Current Ratio
- 0.97
- Quick Ratio
- 0.97
- Debt to Market Cap
- 0.54
- Net Debt to EBITDA
- 5.09
- Interest Coverage Ratio
- 5.07
Taxes
In the past 12 months, Royalty Pharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Royalty Pharma EV to EBITDA ratio is 25.11, with an EV/FCF ratio of 13.04.
- EV to Sales
- 14.75
- EV to EBITDA
- 25.11
- EV to Free Cash Flow
- 13.04
- EV to Operating Cash Flow
- 13.04
Balance Sheet
Royalty Pharma has EUR 544.86M in cash and marketable securities with EUR 8.59B in debt, giving a net cash position of -EUR 8.04B billion.
- Cash & Marketable Securities
- EUR 544.86M
- Total Debt
- EUR 8.59B
- Net Cash
- -EUR 8.04B
- Net Cash Per Share
- -EUR 18.06
- Tangible Book Value Per Share
- EUR 19.89
Margins
Gross margin is 89.75%, with operating margin of 57.14%, and net profit margin of 25.66%.
- Gross Margin
- 89.75%
- Operating Margin
- 57.14%
- Pretax Margin
- 44.80%
- Net Profit Margin
- 25.66%
- EBITDA Margin
- 58.71%
- EBIT Margin
- 58.57%
Analyst Forecast
The average price target for Royalty Pharma is EUR 63.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 63.88
- Price Target Upside
- 1.94% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 5.84%
- EPS Growth Forecast
- -16.96%
Scores
- Smart Score
- 10
- AI Score
- ―

